drugset / Trial / NCT00216177
Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis
Phase 4
Unknown
112 enrolled
Hvidovre University Hospital
University Hospital, Gentofte, Copenhagen · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to establish whether RA patients with moderate to severe disease activity with unsustainable response to infliximab 3 mg/kg every 8 weeks have better efficacy with adalimumab 40 mg s.c. eow compared to infliximab 3 mg/kg i.v. every 6 weeks.
Timeline
- Start
- 2005-09
- Primary completion
- 2009-01
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |
| Subject | Infliximab | Monoclonal antibody | 3 mg/kg | Intravenous |